Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Lupin Presents Phase 3 Data for Solosec® (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis

Posted On: 2020-08-14 08:01:08 (Time Zone: Arizona, USA)


Lupin Pharmaceuticals Inc. (Lupin) the U.S. based wholly owned subsidiary of Lupin Limited, today announced results from its pivotal Phase 3 clinical trial to assess efficacy and safety of single-dose Solosec® (secnidazole) 2g oral granules in female patients with trichomoniasis, the most common non-viral, curable sexually transmitted infection (STI) in the U.S. The trial results showed a clinically and statistically significant response rate, or microbiological cure, in patients treated with Solosec® as compared to placebo (p<0.001). The data were presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting.

"The efficacy results of the Phase 3 study are quite encouraging and could support the utility of Solosec® in clinical practice as a treatment option for trichomoniasis once the new indication is approved," said Christina Muzny, M.D., MSPH, University of Alabama at Birmingham, who presented the abstract at IDSOG. "Trichomoniasis increases risk of HIV infection, disproportionately affects African American women and can lead to adverse health outcomes. It is critical to screen women at high risk and treat with therapy that is convenient to use, to help improve patient compliance."

Based on the data, Lupin will submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Solosec® for the treatment of trichomoniasis later this year. Solosec® is only currently approved by the FDA to treat bacterial vaginosis (BV) in adult women.

The trial titled "A Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind study to evaluate the effectiveness and safety of a single oral dose of 2 grams of secnidazole for the treatment of trichomoniasis in women," met its primary endpoint of microbiological cure at the test-of-cure (TOC) visit on study Day 6-12. Microbiological cure was defined as a negative trichomonas vaginalis culture (i.e., InPouch™ TV test negative for T. vaginalis) in the modified Intent-To-Treat (mITT) population (all randomized subjects who were culture positive for T. vaginalis and negative for gonorrhea and chlamydia at baseline). In the trial, 92.2% of patients in the Solosec® group (59/64) achieved the primary endpoint versus 1.5% (1/67) in the placebo group (p<0.001). In the Per-Protocol population, the cure rate was 94.9% (56/59) for Solosec® versus 1.7% (1/60) for placebo (p<0.001). Solosec® was generally well-tolerated. The most commonly reported adverse events were vulvovaginal candidiasis (2.7%) and nausea (2.7%). No serious adverse events were observed in the trial.

"Trichomoniasis is the most common non-viral, STI that impacts an estimated 3-5 million people in the U.S.," Gregory Kaufman, M.D., Senior Vice President, Global Clinical and Medical Affairs, Specialty at Lupin said. "We look forward to working with the FDA as we file for this new indication."

Shares of LUPIN LTD. was last trading in BSE at Rs.1018.85 as compared to the previous close of Rs. 930.4. The total number of shares traded during the day was 966104 in over 25630 trades.

The stock hit an intraday high of Rs. 1023.4 and intraday low of 932.5. The net turnover during the day was Rs. 968771822.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Oberoi Realty Limited board to announce Q3 results on Jan 22, 2021

PG Electroplast Ltd board to consider Q3FY21 results on Jan 25, 2021

TGV Sraac Ltd board to approve 3rd quarter results on Jan 25, 2021

Natural Capsules Ltd board to announce third quarter results on Jan 25, 2021

India Grid Trust board to consider distribution, financial information on Jan 22, 2021

High Energy Batteries India Ltd board to approve quarterly results on Feb 6, 2021

Security and Intelligence Services (India) Ltd board to consider Q3FY21, 9MFY21 results on Feb 3, 2021

Stylam Industries Limited board to announce third quarter results on Jan 25, 2021

Phillips Carbon Black Ltd board to approve interim dividend on Jan 20, 2021

Shriram City Union Finance Ltd board to consider 3rd quarter results on Jan 29, 2021

Shreyans Industries Ltd board to approve quarterly results on Feb 11, 2021

Firstsource Solutions Ltd board to announce Q3FY21 results on Feb 9, 2021

3i Infotech Ltd board to consider Q3 results on Jan 28, 2021

HDFC Bank's Net NPA at 0.09%

HDB Financial Services Limited reports loss of Rs. 44.3 crore in Q3FY21

HDFC Bank increases distribution network YoY

HDFC Bank's balance sheet size grows 18.6% YoY

HDFC Securities Limited posts PAT of Rs. 166.6 crore in Q3FY21

HDFC Bank's Capital Adequacy Ratio was at 18.9% as of Dec 31, 2020

Parmax Pharma Limited approves preferential issue

Rossari Biotech Ltd board to approve quarterly results on Jan 23, 2021

Aditya Vision Limited opens 57th showroom

JBM Auto Limited receives orders for supply of 700 JBM CITYLIFE buses

Gujarat Hotels Ltd posts net profit of Rs. 0.58 crore in Q3FY21

Sacheta Metals Ltd Q3FY21 net profit at Rs. 0.89 crore

HDFC Bank Ltd Q3FY21 consolidated PAT climbs to Rs. 8769.33 crores

Star Cement Limited commences commercial production of new grinding unit

Chembond Chemicals Ltd Q3FY21 consolidated PAT zooms to Rs. 8.44 crore

Apollo Pipes Ltd reports net profit of Rs. 16.33 crores in Q3 FY2020-21

Apollo Hospitals begins vaccinating healthcare workers

International Travel House Ltd Q3FY21 loss at Rs. 10.69 crore

GE T&D India Limited to sell its GLobal Engineering Operations Division

IRB InvIT Fund to distribute Rs. 2.50 per unit for Q3 FY21

Smruthi Organics Ltd board recommends 2:1 bonus shares

Smruthi Organics Ltd Q3FY21 net profit drops QoQ to Rs. 5.10 crore

SpiceJet to connect Delhi with Sikkim with a daily non-stop flight

Indian Railway Finance Corporation Ltd raised Rs 1398.63 crores from 31 anchor investors ahead of its public issue

CRISIL A1+ rating reaffirmed to PNB Gilts Ltd's Rs. 1000 commercial paper programme

Pudumjee Paper Products Ltd board to announce Q3 results on Jan 23, 2021

SML ISUZU Ltd board to consider Q3FY21 results on Feb 5, 2021

Indian Energy Exchange Ltd board to consider interim dividend on Jan 21, 2021

LIC Housing Finance Ltd board to announce 3rd quarter results on Jan 29, 2021

CARE Ratings Ltd board to consider dividend, Q3 results on Feb 6, 2021

The Dharamsi Morarji Chemical Company Limited board to approve third quarter results on Feb 8, 2021

IDBI Bank Ltd board to announce 3rd quarter results on Jan 28, 2021

Reliance Industries Ltd board to consider Q3FY21, 9MFY21 results on Jan 22, 2021

Tata Consumer Products Ltd board to announce Q3FY21 results on Feb 2, 2021

Visaka Industries Ltd board to consider Q3 results, interim dividend on Jan 28, 2021

EIH Ltd board to announce third quarter results on Jan 29, 2021

Vardhman Textiles Ltd board to approve quarterly results on Jan 21, 2021



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020